Simulations Plus, Inc. SLP

Simulations Plus, Inc. es un proveedor en el sector biofarmacéutico, que ofrece software avanzado y servicios de consultoría que mejoran el descubrimiento, desarrollo, investigación, operaciones de ensayos clínicos, presentaciones regulatorias y comercialización de medicamentos. Las soluciones de bio simulación integrales de la compañía incluyen inteligencia artificial/aprendizaje automático (IA/ML), farmacocinética basada en la fisiología, biofarmacéutica basada en la fisiología, farmacología/toxicología de sistemas cuantitativos y enfoques de modelado de PK/PD poblacional. Opera a través de dos segmentos: software y servicios. Ofrece productos de software para investigación, desarrollo y comercialización farmacéutica, incluyendo GastroPlus, DDDPlus, MembranePlus, ADMET Predictor, MedChem Designer, DILIsym, NAFLDsym, ILDsym, IPFsym y otros. Además, también ofrece soluciones de rendimiento e inteligencia habilitadas para la simulación junto con soporte de comunicaciones médicas para el desarrollo clínico y comercial de medicamentos.

SLP hizo una división de acciones (split) de 2:1 el 2 de octubre de 2007: cada acción se convirtió en 2. Cambió la cantidad de acciones y su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 23 sept

  Biosimulation Market Set for Strong Growth Through 2035, Fueled by AI-Driven Drug Discovery, Virtual Trials and Precision Medicine Demand

  The global biosimulation market reached USD 4.09 billion in 2025 and is projected to grow at 16.90% CAGR through 2035, reaching USD 19.49 billion. Growth is driven by AI-driven drug discovery, virtual clinical trials, personalized medicine demand, and computational modeling adoption. However, geopolitical instability in the Middle East has created near-term supply chain disruptions and increased pharmaceutical packaging costs by 15-20%. Key players are pursuing strategic acquisitions and platform launches to expand capabilities.

  

• GlobeNewswire Inc. 6 ago

  Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

  Johnson Fistel is investigating Simulations Plus (SLP) after the company cut its fiscal 2025 revenue guidance from $90-93 million to $76-80 million in June 2025, citing budget reductions and project delays. The stock fell 24% following the announcement. In July, the company reported a $67.3 million net loss including a $77.2 million impairment charge and dismissed its auditor Grant Thornton, which cited unresolved concerns about segment reporting and internal controls, triggering another 26% stock decline.

  

• GlobeNewswire Inc. 10 jul

  Halper Sadeh LLC is Investigating Whether SLP, HUN, OLN, PULM are Obtaining Fair Deals for their Shareholders

  Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to proposed mergers and acquisitions. The investigations concern whether shareholders are receiving fair consideration in these transactions, with concerns that insiders may benefit disproportionately and deal terms may prevent superior competing offers.

  

• GlobeNewswire Inc. 8 jul

  Halper Sadeh LLC is Investigating Whether CRNX, ESI, INVE, SLP are Obtaining Fair Deals for their Shareholders

  Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholders' interests.

  

• GlobeNewswire Inc. 26 jun

  [Latest] Global In Silico Clinical Trials Market Size/Share Worth USD 8.94 Billion by 2035 at a 15.2% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

  The global in silico clinical trials market, valued at USD 1.84 billion in 2025, is projected to grow to USD 8.94 billion by 2035 at a 15.2% CAGR. Growth is driven by high failure rates in traditional clinical trials, regulatory acceptance of computational evidence, advances in AI and digital twins, and ethical concerns about animal testing. North America dominates the market while Asia Pacific shows the fastest growth.